» Articles » PMID: 34244902

Progression of Functional Gait in Hereditary Spastic Paraplegias

Overview
Journal Cerebellum
Publisher Springer
Specialty Neurology
Date 2021 Jul 10
PMID 34244902
Citations 6
Authors
Affiliations
Soon will be listed here.
Abstract

Hereditary spastic paraplegias (HSP) are characterized by progressive deterioration of axonal projections of upper motor neurons leading to abnormal locomotion. The clinical course of HSP as well as the definition of the best instruments to assess its progression is largely unknown. The aim of this study was to investigate the progression of functional gait in individuals with HSP and to define sensitivity to change, minimal clinically important difference (MCID), and validity of timed functional tests of gait (TFT). The study was constituted of two phases: a cross-sectional study and a prospective cohort of 18 months. Twenty-five patients (17 being SPG4), and twenty-five age- and sex-matched control individuals performed TFT. Spastic paraplegia rating scale (SPRS), ten-meter walking test (10MWT), timed up and go test (TUG), both at self-selected and maximal walking speeds, and six-minute walking test (6MWT) were performed on baseline in both groups and after 18 months of follow-up only in the HSP cohort. In the cross-sectional analysis, all TFTs performances were greatly impaired in HSP patients compared to controls. After 18 months of follow-up, TFTs did not differ significantly from baseline in the statistical analysis, with some tests showing more frequent improvement than worsening. We have provided effect size measures and MCID for the evaluated instruments. HSPs clearly compromised TFTs performances, which were valid instruments for assessing disease severity. However, TFTs and SPRS did not capture the very slow motor evolution of HSPs, reinforcing the necessity of additional biomarkers of disease progression.

Citing Articles

Designing and Validating a Hereditary Spastic Paraplegia-Specific Quality of Life Rating Scale (HSPQoL).

Siow S, Fleming J, Barlow-Stewart K, Wali G, Kumar K, Sue C Cerebellum. 2024; 24(1):14.

PMID: 39681739 PMC: 11649815. DOI: 10.1007/s12311-024-01771-1.


Long-term progression of clinician-reported and gait performance outcomes in hereditary spastic paraplegias.

Cubillos Arcila D, Dariva Machado G, Martins V, Leotti V, Schule R, Peyre-Tartaruga L Front Neurosci. 2023; 17:1226479.

PMID: 37811319 PMC: 10556702. DOI: 10.3389/fnins.2023.1226479.


Outcome Measures and Biomarkers for Clinical Trials in Hereditary Spastic Paraplegia: A Scoping Review.

Siow S, Yeow D, Rudaks L, Jia F, Wali G, Sue C Genes (Basel). 2023; 14(9).

PMID: 37761896 PMC: 10530989. DOI: 10.3390/genes14091756.


Automated assessment of foot elevation in adults with hereditary spastic paraplegia using inertial measurements and machine learning.

Ollenschlager M, Hofner P, Ullrich M, Kluge F, Greinwalder T, Loris E Orphanet J Rare Dis. 2023; 18(1):249.

PMID: 37644478 PMC: 10466820. DOI: 10.1186/s13023-023-02854-8.


Mobile digital gait analysis objectively measures progression in hereditary spastic paraplegia.

Loris E, Ollenschlager M, Greinwalder T, Eskofier B, Winkler J, Gassner H Ann Clin Transl Neurol. 2023; 10(3):447-452.

PMID: 36622133 PMC: 10014001. DOI: 10.1002/acn3.51725.


References
1.
Shribman S, Reid E, Crosby A, Houlden H, Warner T . Hereditary spastic paraplegia: from diagnosis to emerging therapeutic approaches. Lancet Neurol. 2019; 18(12):1136-1146. DOI: 10.1016/S1474-4422(19)30235-2. View

2.
DeLuca G, Ebers G, Esiri M . The extent of axonal loss in the long tracts in hereditary spastic paraplegia. Neuropathol Appl Neurobiol. 2004; 30(6):576-84. DOI: 10.1111/j.1365-2990.2004.00587.x. View

3.
Burguez D, Polese-Bonatto M, Scudeiro L, Bjorkhem I, Schols L, Jardim L . Clinical and molecular characterization of hereditary spastic paraplegias: A next-generation sequencing panel approach. J Neurol Sci. 2017; 383:18-25. DOI: 10.1016/j.jns.2017.10.010. View

4.
Klimpe S, Schule R, Kassubek J, Otto S, Kohl Z, Klebe S . Disease severity affects quality of life of hereditary spastic paraplegia patients. Eur J Neurol. 2011; 19(1):168-71. DOI: 10.1111/j.1468-1331.2011.03443.x. View

5.
Schule R, Wiethoff S, Martus P, Karle K, Otto S, Klebe S . Hereditary spastic paraplegia: Clinicogenetic lessons from 608 patients. Ann Neurol. 2016; 79(4):646-58. DOI: 10.1002/ana.24611. View